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 ABSTRACT 27 
Influenza A viruses (IAVs) are common pathogens of birds that occasionally 28 
establish endemic infections in mammals. The processes and mechanisms that 29 
result in IAV mammalian adaptation are poorly understood. The viral non-structural 1 30 
(NS1) protein counteracts the interferon (IFN) response, a central component of the 31 
host-species barrier.  32 
We characterised the NS1 proteins of equine influenza virus (EIV), a mammalian IAV 33 
lineage of avian origin. We showed that evolutionary distinct NS1s counteract the 34 
IFN response using different and mutually exclusive mechanisms: while the NS1s of 35 
early EIVs block general gene expression by binding to the cellular polyadenylation 36 
specific factor 30 (CPSF30), NS1s from more evolved EIVs specifically block the 37 
induction of IFN-stimulated genes by interfering with the JAK/STAT pathway. These 38 
contrasting anti-IFN strategies are associated with two mutations that appeared 39 
sequentially and became rapidly selected during EIV evolution, highlighting the 40 
importance of evolutionary processes on immune evasion mechanisms during IAV 41 
adaptation. [150 words] 42 
 43 
IMPORTANCE 44 
Influenza A viruses (IAVs) infect certain avian reservoir species, and occasionally 45 
transfer to and cause epidemics of infections in some mammalian hosts. However, 46 
the processes by which IAVs gain the ability to efficiently infect and transmit in 47 
mammals remains unclear. H3N8 equine influenza virus (EIV) is an avian-origin virus 48 
that has successfully established a new lineage in horses in the early 1960, and is 49 
currently circulating worldwide in the equine population. Here we analysed the 50 
molecular evolution of the virulence factor non-structural protein 1 (NS1) and show 51 
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 that NS1s from different time periods after EIV emergence counteract the host innate 52 
immune response using contrasting strategies, which are associated with two 53 
mutations that appeared sequentially during EIV evolution. The results shown here 54 
indicate that the interplay between virus evolution and immune evasion plays a key 55 
role in IAV mammalian adaptation. [139 words] 56 
 57 
INTRODUCTION 58 
Influenza A viruses (IAVs) have caused several epizooties in various animal species 59 
and four pandemics in humans in the last hundred years. The main natural reservoir 60 
of IAVs is wild water birds of various types, but these viruses also circulate in some 61 
mammalian host populations – including humans, pigs, horses and dogs (1). 62 
However, most infections of mammals by avian IAVs result in either spillover 63 
infections or isolated outbreaks (1) (2) and very few have resulted in the 64 
establishment of novel endemic lineages. The reasons underlying the establishment 65 
of an avian-origin IAV in a mammalian host are still only partially understood.  66 
In most cases it appears that emerging IAVs have to overcome multiple barriers to 67 
infect and become established in a new host. For example, the presence of 68 
particular forms or linkages of sialic acids within the respiratory tract can facilitate or 69 
impair binding by the viral hemagglutinin (HA) or the activity of the viral 70 
neuraminidase (NA) (3) (4). Other incompatibilities between IAVs and host proteins 71 
can also account for the species barrier as it has been recently shown that ANP32A 72 
is a host factor that is required for optimal function of the IAV polymerase complex 73 
(5). Molecular incompatibilities can sometimes be overcome by adaptive mutations in 74 
the virus, and the high mutation rates exhibited by IAVs can facilitate their 75 
appearance. The role of mutations in HA in virus-host interaction are among the best 76 
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 characterised (6), but mutations in other viral segments including those in PB2, NP, 77 
NA, M, or NS have also been described (7)  (8) (9). However, the roles of the latter in 78 
post-transfer adaptation are still incompletely understood.  79 
IAV non-structural protein 1 (NS1) is encoded by segment eight and possesses two 80 
functionally distinct domains: a N-terminal RNA binding domain (RBD) (amino acids 81 
1-73), and a C-terminal effector domain (ED) (85-end) separated by a short and 82 
flexible linker region (10) (11). The last 25 residues of NS1 are thought to form a 83 
disordered and flexible “tail” (10). Molecular interactions with multiple host proteins 84 
allow NS1 to perform a remarkable number of activities (12). One of the best-85 
described functions of NS1 is its ability to antagonise the innate immune response, 86 
predominantly the production of type I interferons (IFN). The type I IFN response is 87 
an essential component of the host barrier that plays a critical role against emerging 88 
viruses, as the recipient hosts usually lack pre-existing immunity. A variety of 89 
pathogen recognition receptors (PRRs) recognise pathogen-associated molecular 90 
patterns (PAMPs) and activate a cascade of events that lead to the production and 91 
secretion of type I IFN (13). Secreted type I IFN binds to its receptor in both infected 92 
and neighboring cells and activates the Janus kinase/signal transducers and 93 
activators of transcription (JAK/STAT) pathway, which in turn results in the assembly 94 
of a protein complex, referred to as interferon-stimulated gene factor 3 (ISGF3), 95 
which is composed of phospho-STAT1, phospho-STAT2 and interferon regulatory 96 
factor 9 (IRF9). This complex will translocate to the nucleus, bind to DNA regulatory 97 
sequences containing IFN-stimulated response elements (ISREs), and stimulate the 98 
transcription of hundreds of IFN-stimulated genes (ISGs) including interferon-99 
stimulated gene 15 (ISG15), myxovirus resistance protein 1 (MX1), and 2’-5’-100 
oligoadenylate synthetase 1/2/3 (OAS1/2/3). As a result, IFN-stimulated cells will 101 
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 establish an antiviral state to protect against different viruses, including IAVs (13) 102 
(14). 103 
H3N8 equine influenza virus (EIV) is an avian-origin virus lineage that has been 104 
circulating in horses since at least 1963 (15) (16) and thus provides a model for the 105 
long-term mammalian adaptation of avian-derived IAVs. Phylogenetic studies have 106 
shown that several amino acid substitutions occurred within each genomic segment 107 
during the evolutionary history of EIV, some of which have been associated with host 108 
adaptation in other IAVs (17). However, the role of any of those mutations in EIV 109 
adaptation to horses is unclear. We hypothesized that the evolution of NS1 would be 110 
part of the adaptive process of EIV to horses. To test this hypothesis, we 111 
characterized the NS1 genes of a group of evolutionary distinct EIVs using a 112 
combination of approaches that included experimental infections, reverse genetics, 113 
site-directed mutagenesis, phylogenetics and transcriptomics.  114 
 115 
RESULTS 116 
Evolutionary distinct NS1 proteins of the H3N8 EIV lineage exhibit marked 117 
functional differences. To experimentally study the functional evolution of the 118 
H3N8 EIV NS1 proteins, we selected 13 H3N8 EIVs that included at least one 119 
representative virus per decade since its first isolation in 1963 (Table 1) and cloned 120 
the coding sequence of their NS1 proteins into a pCAGGS expression plasmid.  121 
As the F2/F3 region of CPSF30 involved in interaction with influenza NS1 proteins is 122 
conserved between human and equine species (data not shown) and the 123 
transfection efficiency of 293T cells is highly superior as the one of E-derm cells 124 
(data not shown), we used 293T cells to study the functional evolution of EIV NS1. 125 
To compare the ability of each individual NS1 protein to limit the production of IFN-β 126 
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 we co-transfected 293T cells with NS1 expression plasmids or with an empty vector 127 
(pCAGGS), together with a plasmid expressing Firefly luciferase under the IFN- 128 
promoter (pIFN--FF-Luc), and with a constitutively active Renilla luciferase (pREN-129 
Luc) expression plasmid to normalize for the transfection efficacy. At 24 hpt, cells 130 
were infected with SeV, a well-described IFN- inducer. As expected, SeV infection 131 
resulted in a strong activation of the IFN- promoter in cells co-transfected with the 132 
empty vector (Figure 1A) (set to 100%) compared to uninfected control cells. 133 
However, SeV activation of the IFN-β promoter was blocked in cells transfected with 134 
the different EIV NS1 expressing plasmids used in this study (Figure 1A). 135 
We also compared the ability of these NS1 proteins to block the induction of ISGs 136 
upon IFN treatment. To this end, we co-transfected 293T cells with the NS1 137 
expression plasmids described above together with a plasmid expressing the Firefly 138 
luciferase under the control of a promoter containing an IFN-stimulated regulatory 139 
element (pISRE-FF-Luc), and again used pREN-Luc as an internal control. At 24 hpt, 140 
we treated the cells with uIFN (500 units/well) to stimulate the ISRE-containing 141 
promoter and 18 h later we measured FF-Luc and REN-Luc activities. The NS1 142 
proteins of EIVs isolated in 1963 (so called ‘Early’: U/63 and M/63) displayed a 143 
relatively low repression of the ISRE-containing promoter (Figure 1B), and the 144 
antagonistic property of NS1 over this promoter increased in EIVs that circulated 145 
between 1969 and 1995 (SP/69, F/79, S/89, K/91, LP/95, K/95). Furthermore, the 146 
NS1 proteins of EIVs isolated between 1999 and 2013 (so called ‘Late’: K/99, K/02, 147 
O/03, N/03, M/13) showed a variable control of the ISRE-containing promoter 148 
depending on the NS1 protein tested (Figure 1B). 149 
To assess the ability of the NS1 proteins to inhibit general gene expression we 150 
performed co-transfections of the individual NS1-expression plasmids together with 151 
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 pREN-Luc and measured luciferase activity 24 h later. The NS1 proteins of EIVs that 152 
circulated in the 1960s strongly blocked the otherwise constitutively active Renilla 153 
luciferase (Figure 1C). In contrast, the NS1 proteins of EIVs isolated after 1979 did 154 
not block general gene expression as REN-Luc expression wasn’t strongly reduced. 155 
In addition, in some cases NS1 expression was associated with an increase in 156 
luciferase expression (Figure 1C), as described for other NS1 proteins (18). We also 157 
examined the expression levels of NS1 by Western blot in parallel transfected cell 158 
lysates. As expected, the NS1 proteins that strongly block general gene expression 159 
(i.e. U/63, M/63, SP/69) could not be detected, probably because of the ability of 160 
these NS1s to inhibit their own synthesis (19, 20) (Figure 1D). On the other hand, 161 
NS1 proteins that did not block host gene expression (F/79 to M/13) were easily 162 
detected. Interestingly, the level of expression of NS1 proteins of viruses isolated 163 
between 1979 and 1995 (F/79 to LP/95) was lower than that of more recent NS1 164 
proteins (K/95 to M/13). 165 
Taken together, these results suggest that the NS1 proteins of the H3N8 EIV lineage 166 
maintained a strong control over IFN-β production throughout evolution, while 167 
progressively increasing their control of IFN-stimulated signal transduction. Such 168 
control mechanisms are likely independent of the NS1-mediated control of general 169 
gene expression, as the NS1 proteins of EIVs that circulated after 1969 lost that 170 
ability. These results suggest a direct effect of these NS1 proteins on IFN signaling 171 
pathway. 172 
Amino acid 186 and the C-terminal tail affect EIV NS1 protein function. To 173 
identify the mutations responsible for the stepwise chronological changes in EIV NS1 174 
function we first examined a multiple sequence alignment of the NS1 proteins used 175 
in our studies (Figure 1E). While various amino acid changes were observed, the 176 
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 most evident was an 11-amino acid truncation in the carboxy-terminus (C-terminus) 177 
that appeared in 1999 (21), as well as the appearance of two amino acid 178 
substitutions in the 1970s - E186K and A112T. The E186K substitution lies within the 179 
putative CPSF30-binding domain and notably, this substitution took place at the 180 
same time as the loss of repression of general gene expression by EIV NS1 (Figure 181 
1C). 182 
To determine the impact of the E186K substitution and the C-terminal truncation on 183 
NS1 function, we introduced mutations in the NS1 gene of A/equine/Ohio/2003 184 
(O/03), a virus isolated after 40 years of continuous EIV circulation in horses. The 185 
NS1 protein of O/03 (O/03) is 219 amino acids long (naturally truncated) and 186 
possesses a lysine at position 186 (represented as Late NS1 in Figure 2A). Three 187 
NS1 revertant viruses were tested: a K186E substitution (O/03-K186E), a C-terminal 188 
extension of 11 amino acids (O/03-230), and the double change of the extended 189 
NS1 and the K186E substitution together (O/03-K186E-230) (Figure 2A). The O/03-190 
230 NS1 revertant would therefore represent the Intermediate (Interm.) NS1 proteins 191 
of EIVs that circulated between 1979 and 1995 (F/79, S/89, K/91, LP/95, K/95) 192 
(Figure 2A), while the NS1 double revertant represents Early NS1 proteins of EIVs 193 
that circulated between 1963 and 1969 (U/63, M/63, SP/69) (Figure 2A).  To 194 
determine the impact of a glutamic acid residue at position 186, we introduced a 195 
K186E mutation in the O/03 NS1 (Artificial). However, it should be noted that such 196 
revertant has not been detected in nature. 197 
The presence of a glutamic acid at position 186 in O/03-K186E and O/03-K186E-230 198 
was associated with a decreased ability to control the IFN- promoter (Figure 2B), a 199 
decreased capacity to control the activity of the ISRE-containing promoter (Figure 200 
2C), and a strong repression of the constitutively expressed promoter compared to 201 
 o
n
 D
ecem
ber 19, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 O/03 and O/03-230 revertant (Figure 2D).  Consistent with this result, NS1 proteins 202 
harbouring E186 were not detectable by Western blot (Figure 2E).  203 
Since NS1 binding to CPFS30 is known to block general gene expression (12), we 204 
performed co-immunoprecipitation assays using an equine CPSF30 and NS1 O/03 205 
and revertant proteins expressed in vitro. We confirmed that the presence of E186 206 
determines CPSF30 binding, regardless of the length of NS1 (Figure 3). It should be 207 
noted that binding of NS1 to CPSF30 is consistent with the inhibition of NS1 208 
expression upon transfection (Figure 1D and 2D). This is because transcription from 209 
the pCAGGS plasmid is driven by a polymerase-II (pol-II)-dependent promoter 210 
through the binding to CPSF30. 211 
Overall, these results suggest that the NS1 proteins of early EIVs were able to 212 
control general gene expression through CPSF30 binding, and that K186E 213 
substitution, which arose in NS1 after approximately 10 years post viral emergence, 214 
influenced the control of IFN and ISG induction. Moreover, this substitution seems to 215 
have released the block of general gene expression and improved NS1 ability to 216 
control IFN-mediated signal transduction. 217 
Mutations in NS1 acquired throughout evolution affect virus replication and 218 
cell-to-cell spread. Three individual O/03 revertant viruses were generated and 219 
tested for growth in MDCK cells: one carrying the K186E substitution (O/03-K186E), 220 
another carrying the C-terminus extension (O/03-230); and another one carrying 221 
both changes (O/03-K186E-230). As indicated in Figure 4A, none of the introduced 222 
changes modified the NEP amino acid sequence. While the O/03-K186E and O/03-223 
230 viruses exhibited similar growth kinetics as the O/03 (Figure 4B), the double 224 
revertant O/03-K186E-230 displayed a faster replication rate until 12 hpi, but never 225 
reached a titre as high as the three other viruses over 72 h (Figure 4B).  226 
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 In equine cells, the O/03 virus showed a significant advantage over all revertant 227 
viruses after 24 hpi. Indeed, O/03 peaked at a titre three to four logs higher than the 228 
revertants between 24 and 72 hpi (Figure 4B). Interestingly, during the first 16 hpi, 229 
no difference in growth kinetics was observed between O/03 and natural revertant 230 
viruses (O/03-230 and O/03-K186E-230). More importantly, O/03-K186E-230 231 
displayed the highest replication rate during the first 12 hpi, reaching a titre two logs 232 
higher than any other viruses tested. The O/03-K186E revertant, which expressed an 233 
NS1 protein that was never isolated in nature, showed a strong attenuation 234 
compared to O/03 between 16 and 72 hpi. 235 
When we tested the ability of O/03 and revertant viruses to spread among 236 
neighbouring cells by examining their plaque phenotype in MDCK cells, all revertant 237 
viruses displayed significantly smaller plaques than O/03 (Figure 4C), and the O/03-238 
K186E-230 revertant was the most affected, showing pinpoint plaques. This 239 
suggested that NS1 evolution resulted in a more efficient cell-to-cell spread.  240 
As NS1 proteins harbouring E186 bind CPSF30 we wanted to check if during viral 241 
infection NS1 would be present in the same intracellular compartment as CPSF30 242 
(i.e. the nucleus). All proteins exhibited similar nucleocytoplasmic localisation 243 
patterns (Figure 4D), which suggests that the introduced mutations did not affect 244 
NS1 sub-cellular localization. 245 
NS1 amino acid 186 and the length of the C-terminal tail are key determinants 246 
of EIV control of cellular protein synthesis and the establishment of an 247 
antiviral state in equine cells. To compare the viruses’ ability to limit the 248 
establishment of an antiviral state we infected equine cells (MOI 0.1) with each of the 249 
viruses and monitored the expression of two ISGs (ISG15 and MX1) by Western blot 250 
at different hpi. As expected, ISG15 and MX1 were detected in lysates of cells 251 
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 infected with both the O/03-230 and O/03-K186E-230 revertant viruses, but not the 252 
O/03 (Figure 5A) at 24 hpi. We did not detect those proteins in cells infected with 253 
O/03-K186E.  254 
To determine the effects of the NS1 revertants on the synthesis of cellular proteins, 255 
we performed puromycin assays at various hpi in equine cells (22). Puromycin will 256 
be incorporated at the C-terminus of all nascent proteins (23). After cell lysis, an 257 
immunoblotting against puromycin is performed to allow the detection of nascent 258 
proteins of various sizes (appearing as a black smear) that were being at the 259 
moment of cell lysis. The darker and longer the smear is, the more proteins are 260 
being produced at the moment of cell lysis. The double revertant virus (O/03-K186E-261 
230) induced a strong protein shutoff (Figure 5B), particularly at early times post 262 
infection, and that was associated with high expression levels of NS1 from 8 to 24 263 
hpi (Figure 5A). As expected, the presence of E186 did not lead to self-inhibition 264 
upon infection (in contrast with the self-inhibition of NS1 observed in transfections, 265 
see Figure 3). This is because during viral infections the viral polymerase complex 266 
drives transcription of NS1 and this process does not require CPSF30. Differences in 267 
molecular mechanisms between transfections and infections have also been 268 
previously reported in the literature (18, 24, 25). While this result is consistent with 269 
E186 playing an important role in blocking general gene expression via a CPSF30-270 
dependent mechanism, it also suggests that a complementary role of NS1 C-271 
terminal tail might be necessary to induce a strong protein shutoff, as O/03-K186E 272 
did not block protein synthesis at any time pi (Figure 5B). However, we cannot rule 273 
out the possibility that this lack of protein shutoff was due to a low infection level or 274 
low expression of O/03-K186E NS1 protein in equine cells, likely due to a strong 275 
attenuation of this virus in equine cells (Figure 6A).  276 
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 Interestingly, the O/03 virus induced a significant increase of protein synthesis at 12 277 
hpi, and a low but significant protein shutoff at 24 hpi (Figure 5B). 278 
As the double revertant virus (O/03-K186E-230) induced a strong protein shutdown 279 
and an early antiviral state, we assumed that the cellular homeostasis would be 280 
compromised and the cells would undergo apoptosis prematurely. To test this 281 
hypothesis, we compared the expression levels of caspase 3 (cleaved and total) in 282 
O/03 and revertant virus-infected E-derm cells (MOI 0.1) at different times pi (Figure 283 
5A). As expected, cleavage of caspase 3 was already detectable at 24 hpi in cells 284 
infected with the O/03-K186E-230 revertant virus. Interestingly, the O/03-230 285 
revertant virus also induced premature apoptosis, suggesting that the tail of NS1 286 
plays a role in controlling programmed cell death. 287 
EIV O/03 grows to high levels despite eliciting high amounts of antiviral 288 
cytokines and can replicate in IFN-primed equine cells. To assess whether the 289 
IFN system was the limiting factor of O/03 revertant virus replication, we measured 290 
the antiviral activity of the supernatant of equine cells infected with the viruses (MOI 291 
0.1) at different times pi using a rVSV-GFP-based bioassay (26) and compared it 292 
with the growth kinetics of each virus (Figure 6). Surprisingly, the highest level of 293 
antiviral cytokines was produced upon O/03 infection, peaking at 24 hpi (Figure 6A). 294 
This did not seem to affect viral growth since this virus reached rapidly a very high 295 
titre (107 PFU/ml at 24 hpi), as previously shown (Figure 4B). The pattern of antiviral 296 
cytokine production compared to viral growth was similar between O/03-230 and 297 
O/03-K186E-230 revertant viruses (Figures 6C and D, respectively), where low 298 
levels of antiviral cytokines were associated with limited virus growth. In contrast, 299 
cells infected with the O/03-K186E revertant virus exhibited a significantly high peak 300 
of antiviral cytokines at 8 hpi that seemed to control virus growth effectively (Figure 301 
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 6B), since we couldn’t detect any viral growth at later times pi. Consistent with this, 302 
the level of antiviral cytokines decreased progressively and reached a plateau at 16 303 
hpi (Figure 6B). 304 
As the O/03 virus (but not the NS1 revertants) was able to replicate to high levels in 305 
the presence of antiviral cytokines we wanted to determine if it was able to replicate 306 
in cells in an antiviral state induced by exogenous IFN. E-derm cells were pretreated 307 
with 500U of uIFN for 24 h, and then inoculated with O/03 and NS1 revertant viruses 308 
(MOI 0.1). While all the viruses exhibited a reduction in virus growth compared to 309 
their observed replication ability in untreated E-derm cells, the O/03 virus reached a 310 
titre of 105 PFU/ml at 24 hpi, significantly higher than the three other viruses (Figure 311 
7A). These results show that the evolution of NS1 resulted in an increased ability to 312 
replicate in cells that have been exposed to uIFN. 313 
To confirm the role of IFN in limiting the replication of the NS1 revertant viruses we 314 
treated equine cells 24h prior to infection (MOI 0.1) with Ruxolitinib to block the 315 
JAK/STAT pathway and thus impaired the ability of the cells to respond to IFN (27). 316 
We compared the growth kinetics of each virus (Figure 7B) in the presence of 317 
Ruxolitinib. Although the O/03 virus maintained a significantly higher titre than the 318 
three other viruses at 24 and 48 hpi, the revertant viruses reached a higher titre than 319 
in normal condition (Figure 4B), confirming the central role of the IFN response in 320 
limiting the replication of O/03 NS1 revertant viruses in equine cells.  321 
The length of NS1 and the nature of residue 186 impacts on EIV-mediated 322 
control of ISG transcription and general gene expression. To identify further 323 
effects of these adaptive mutations on virus-host interactions, we compared the 324 
transcriptomes of equine cells infected with the O/03 and revertant viruses. We first 325 
determined the total number of differentially expressed genes (DEGs) compared to 326 
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 mock infected samples (Figure 8) at 8 hpi (end of eclipse phase in E-derm), in order 327 
to avoid any bias due to different replication efficiency between viruses. Cells 328 
infected with the O/03 virus exhibited the largest number of DEGs to mock-infected 329 
cells (n=429), which correlates with an increased production of proteins at 12 hpi 330 
(Figure 5B), and likely reflects productive infection. Furthermore, the number of 331 
DEGs in revertant virus-infected cells compared to mock-infected samples 332 
decreased as follows: 241 for O/03-230-infected samples, 193 for O/03-K186E-333 
infected samples, and 158 for O/03-K186E-230-infected samples (Figure 8A, a 334 
detailed list of DEGs including Gene ID, gene name, and log2 fold change is shown 335 
in Table S1). This indicates that these two natural mutations in NS1 have a high 336 
impact on the response of equine cells to EIV infection, highlighting their role in virus 337 
adaptation. 338 
As the O/03 virus replicated to high titres despite inducing high levels of antiviral 339 
cytokines, we compared the number of ISGs and interferon-induced elements that 340 
were up-regulated in cells infected with the revertant viruses, but absent in O/03-341 
infected samples (Figure 8B). As expected, a large number of ISGs (i.e. ISG15, 342 
MX1, OAS [1/2/3]) that were maintained at a basal level in cells infected with O/03 343 
were up-regulated in cells infected with the revertant viruses (Figure 8B).  344 
We also looked for variations in viral gene expression between O/03 and revertant 345 
viruses and did not observe any significant differences (data not shown). 346 
EIV NS1 evolved to block the induction of ISGs at a pre-transcriptional level. 347 
Our reporter assays showed that the NS1 proteins that did not bind CPSF30 were 348 
able to control ISRE-containing promoters more efficiently (Figure 1 to 3). The 349 
transcriptomics data showed that cells infected with O/03 (but not the revertants) 350 
exhibited a significant control of ISGs transcripts (Figure 8B) despite inducing high 351 
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 amounts of antiviral cytokines (Figure 6A). Furthermore, experiments using 352 
Ruxolitinib treatment confirmed the central role of the JAK/STAT pathway in limiting 353 
the revertant virus growth in equine cells (Figure 7B). Taken together, these results 354 
suggested that the NS1 of O/03 virus was blocking the induction of ISGs at a pre-355 
transcriptional level and this involved the JAK/STAT pathway. Since the JAK/STAT 356 
signalling pathway, upon IFN stimulation, leads to the transcription of ISGs and this 357 
involves the nuclear translocation of the ISGF3 complex. As a marker of ISGF3 358 
nuclear translocation, we compared the amount of nuclear STAT1 at 8 and 24 hpi in 359 
equine cells infected with O/03 and revertant viruses. As expected O/03 infection did 360 
not result in STAT1 nuclear localization, despite the presence of high levels of 361 
antiviral cytokines (i.e. 24 hpi, Figure 6A). In addition, residue 186 played a central 362 
role in limiting STAT1 nuclear translocation as O/03-K186E virus infection resulted in 363 
abundant nuclear STAT1 (Figure 9A). STAT1 also remained in the cytoplasm of cells 364 
infected with O/03-230 or O/03-K186E-230 revertant virus infection, probably due to 365 
the low level of antiviral cytokines produced (Figure 6C and D). However, we cannot 366 
rule out a possible contribution of NS1 C-terminal tail in the control of STAT1 nuclear 367 
translocation. Furthermore, the observed differences were not due to different levels 368 
of expression of STAT1, as no significant differences in total STAT1 expression in 369 
cell lysates were detected by Western blot (Figure 9B). Finally, the percentage of 370 
infected E-derm at 8 hpi was comparable between O/03 and revertant viruses (data 371 
not shown), and a higher percentage of cells infected with O/03 was found at 24 hpi, 372 
further confirming the significant advantage of O/03 over all revertant viruses after 24 373 
hpi. 374 
 375 
DISCUSSION 376 
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 We investigated the role of NS1 evolution in the post-transfer adaptation of an avian-377 
origin IAV to a mammalian host, focusing on the roles of two mutations that 378 
appeared sequentially during EIV evolution. The E186K appeared early after EIV 379 
emergence, while the 11-amino acid C-terminal truncation appeared ~20 years later. 380 
Our results showed that isogenic viruses carrying the evolved version of NS1 exhibit 381 
significant higher fitness in equine cells. The O/03 virus from 2003 was able to 382 
replicate to high titres despite high levels of cytokines being produced by infected 383 
cells (Figure 6A). This was achieved by blocking the induction of ISGs at a pre-384 
transcriptional level (Figure 8B), which is consistent with the lack of STAT1 nuclear 385 
localisation in infected cells (Figure 9A). The ability to replicate in the presence of 386 
IFN is a significant fitness trait as it not only renders an important arm of the host 387 
antiviral response ineffective, but also acts as a barrier to other respiratory viruses 388 
that might compete for the same ecological niche (i.e. the epithelium of the 389 
respiratory tract). Co-infection experiments will shed light on this issue. 390 
In contrast, an isogenic virus carrying a revertant version of NS1 (O/03-K186E-230) 391 
that mimics the early, more avian-like NS1 proteins of EIV replicated to significantly 392 
lower titres over a 72-hour period in equine cells (Figure 4B). This virus induced a 393 
cellular protein shutdown (Figure 5B), high levels of apoptosis (Figure 5A), and this 394 
was associated with inefficient cell-to-cell spread (Figure 4C). However, O/03-395 
K186E-230 efficiently produced infectious particles at 12 hpi (Figure 4B, 6D). This 396 
suggests that the emerging, non-adapted virus was highly susceptible to the host 397 
IFN response, and therefore relied on blocking general gene expression non-398 
specifically to transiently control the innate immune response. However, this will 399 
likely affect the cellular homeostasis and lead to premature apoptosis, depriving the 400 
virus of the cellular resources it needs to replicate. Thus, high replication efficiency 401 
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 during this early period (Figure 4B) would enhance the chances of onward 402 
transmission. 403 
Early EIV NS1 proteins blocked general gene expression by binding to CPSF30, a 404 
host protein that plays a central role in pre-mRNA processing (12). A group of 405 
residues centred around residue 186 (184 to 188) (25, 28, 29), as well as other 406 
additional residues (103, 106, 108, 125) (19, 20, 30) have been previously shown to 407 
be involved in this function. Interestingly, for EIV that binding ability was lost with the 408 
introduction of K186, a substitution that must have been selectively advantageous for 409 
the virus. This is supported by the fact that it became quickly fixed at the virus 410 
population scale (Figure 10), and because the E186 in a contemporary EIV NS1 411 
resulted in severe restriction of viral replication (Figure 4B and 6B) and cell-to-cell 412 
spread (Figure 4C). That single mutation impaired the ability of EIV to block the 413 
induction of the IFN response (Figure 9A), resulting the release of cellular cytokines 414 
(Figure 6B), and subsequent up-regulation of ISGs (Figure 8B). This results are 415 
consistent with a work we recently published on the evolution of H3N8 canine 416 
influenza virus NS1 protein, a virus that originated from the H3N8 EIV lineage in the 417 
early 2000s (31). 418 
The second evolutionary change in NS1 that became rapidly fixed at the population 419 
level was a C-terminal truncation of the protein that appeared in the mid 1990’s 420 
(Figure 10). While determining the molecular mechanism underpinning the effect of 421 
the C-terminal tail was beyond the scope of this study, our experimental infections 422 
suggested that this truncation also increased viral fitness. Indeed, extending the tail 423 
of NS1 reduced virus replication (Figure 4B and 6C) and plaque size (Figure 4C), 424 
increased viral susceptibility to IFN (Figure 7A and 7B), reduced viral control of ISG 425 
transcription (Figure 8B) and expression of ISG15 and MX1 (Figure 5A), and also 426 
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 resulted in an early induction of apoptosis in infected cells (Figure 5A). The later 427 
could be caused by the presence of a putative PDZ-binding domain in the tail of NS1 428 
that has been previously associated with apoptosis (32) (33). Truncation of NS1 429 
would therefore be beneficial for EIV, as it would provide a better control of the IFN 430 
response and extend the lifespan of infected cells.  431 
It is important to note that E186 is present in 98.2% of NS1 unique sequences 432 
derived from avian, human, swine, canine and equine viruses (n=12775, not shown). 433 
However, K186 is more common among equine and canine IAVs. With regard to 434 
NS1 length, the majority (63.7 %) of NS1 proteins are longer than 220 amino acids, 435 
and such "long" NS1s are highly prevalent among IAVs derived from birds, humans, 436 
dogs and horses, but not from pigs as 77% of unique swine NS1 sequences are 437 
shorter than 220 residues. Further experimental work is required to unveil the role of 438 
residue 186 and the C-terminal length of NS1 in the adaptation of IAVs to other 439 
species. 440 
In summary, we have shown that mutations in the NS1 gene that became fixed 441 
during the continuous circulation of EIV in horses led to at least two temporally 442 
distinct changes in NS1 function that resulted in a better control of the mammalian 443 
host innate immune response and likely contributed to the adaptation of an avian-444 
origin virus to its new host, the horse. Comparisons of other mammalian IAV 445 
lineages of avian origin will show whether such dynamic strategies are common 446 
features of influenza A viruses while adapting to mammals. 447 
 448 
MATERIALS AND METHODS 449 
Cells. Madin-Darby Canine Kidney (MDCK: ATCC CCL-34) and Human Embryonic 450 
Kidney (293T; ATCC CRL-11268) cells were grown at 37°C, 5% CO2 in Dulbecco’s 451 
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 modified Eagle’s medium (DMEM) high glucose, GlutaMax and pyruvate 452 
(ThermoFisher Scientific) supplemented with 10% of Fetal Calf Serum (Gibco Life 453 
Technologies), and 1% PS (penicillin, 100 units/ml; streptomycin, 100 μg/ml; Gibco 454 
Life Technologies). Equine Dermal fibroblasts (E-Derm; ATCC CCL-57) were grown 455 
at 37°C, 5% CO2 in DMEM high glucose, GlutaMax and pyruvate supplemented, 456 
15% of Fetal Calf Serum (Gibco Life Technologies), 1% Non-Essential Amino acids 457 
(Gibco, Life Technologies), 1% PS (Gibco Life Technologies). 458 
Viruses. Viral stocks (accession number, abbreviation) of A/equine/Uruguay/1/1963 459 
(ACD85423, U/63), A/equine/Miami/1/1963 (ABY81497, M/63), 460 
A/equine/SaoPaulo/1/1969 (ACD85390, SP/69), A/equine/Fontainebleau/1/1979 461 
(ACD85401, F/79), A/equine/Sussex/1/1989 (ACD97430, S/89), 462 
A/equine/Kentucky/1/1991 (ACA24672, K/91), A/equine/LaPlata/1995 (MF182460, 463 
LP/95), A/equine/Kentucky/1995 (MF182451, K/95), A/equine/Kentucky/1999 464 
(MF182443, K/99), A/equine/Kentucky/5/2002 (ABA42429, K/02), 465 
A/equine/Newmarket/5/2003 (ACI48802, N/03), A/equine/Ohio/1/2003 (ABA42431, 466 
O/03), A/equine/Mongolia/3/2013 (MF182459, M/13) were grown at passage 2 in 467 
MDCK cells (MOI 0.1), then aliquoted and stored at -80oC. 468 
Reverse genetic influenza A/equine/Ohio/1/03 (O/03) H3N8 O/03 and NS1 (O/03-469 
K186E, O/03-230 and O/03-K186E-230) revertant viruses were grown in MDCK cells 470 
at 37°C, 5% CO2. For infections, virus stocks were diluted in infection medium 471 
(DMEM, 0.3% BSA, 1% PS, and 1 μg/ml of tosylsulfonyl phenylalanyl chloromethyl 472 
ketone (TPCK)-treated trypsin (Sigma) (34). 473 
Sendai virus (SeV), Cantell strain, was purchased from Charles River Laboratories 474 
and stored at -80°C. The rVSV-GFP virus stock used in the bioassay assay was 475 
generated by transiently transfecting HEK293T cells in Opti-MEM with an expression 476 
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 plasmid encoding the VSV glycoprotein of surface (pVSV-G) (26) using TransIT-LT1 477 
transfection reagent (Cambridge Biosciences) at 37oC, 5% CO2 for 36h (100mm 478 
sterile dish format, 5 x 106 cells). At the end of the transfection period, the cells were 479 
infected with a previous stock of rVSV-GFP virus (2.5 x 102 TCID50) for 4h at 37
oC, 480 
5% CO2 in growth medium, then washed with PBS and maintained at 37
oC, 5% CO2 481 
in growth medium for a further 16h. The supernatant was then collected and filtered 482 
through a 0.45m filter (Fisher Scientific), before being aliquoted and stored at -483 
80oC. 484 
Cloning of NS1.  Mammalian expression constructs for untagged NS1 used in the 485 
reporter assay were generated as previously described (18) (19). pcDNA3 plasmids 486 
encoding the NS1 were also generated by subcloning from pCAGGS (18). The 487 
sequence of each pCAGGS- or pcDNA3-NS1 inserts were confirmed by Sanger 488 
sequencing and compared to those available in the NCBI Influenza Database. Viral 489 
(v)RNA was extracted from the corresponding viral stocks using the QIAmp Viral 490 
RNA kit (Qiagen), and RNA quality was assessed with NanoDropTM 2000 491 
Spectrophotometer (ThermoFisher Scientific) and stored at -80°C. Reverse 492 
transcription (RT) was done using Uni12 primer (35), 500ng of RNA, and SuperScript 493 
III Reverse Transcriptase (Invitrogen) following the manufacturer's protocol. 494 
Polymerase Chain Reaction (PCR) was done with 100ng of cDNA, PfuUltra II fusion 495 
HS DNA polymerase (Agilent) following the manufacturer's protocol, and a specific 496 
set of primers for each NS1 was used. Cycling parameters and primers are available 497 
upon request.  498 
In order to prevent expression of nuclear export protein (NEP) in the pCAGGS-NS1 499 
plasmids, a silent mutation in the splice acceptor site of NS1 (SAM, splicing acceptor 500 
mutation) was introduced for each construct as previously described in (18) (19).  501 
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 To engineer the three NS1 revertants, Lysine (K)-to-Glutamic acid (E) (codon 186 502 
‘AAA’ changed into ‘GAA’) and Stop Codon-to-Arginine (R) (codon 220 ‘TGA’ 503 
replaced by ‘CGA’), mutations were introduced into the pCAGGS-splice acceptor 504 
revertant O/03 NS1 constructs and the ambisense pDP2002 plasmid encoding O/03 505 
O/03 NS gene using the PFUTurbo DNA polymerase (Agilent) and specific sets of 506 
primers. The presence of introduced mutations was confirmed by Sanger 507 
sequencing. Cycling parameters and primers are available upon request. 508 
Reporter assay. For analysis of IFN-β and ISRE promoter activation and general 509 
gene expression, 293T cells (12-well plate format, 2.5x105 cells/well) were 510 
transiently co-transfected using TransIT-LT1 transfection reagent (Cambridge 511 
Biosciences), with either 50ng of pIFN-β-FF-Luc or 50ng of pISRE-FF-Luc (reporter 512 
plasmids encoding Firefly luciferase [FF-Luc] under the control of the IFN-β promoter 513 
or the ISRE promoter, respectively), 50ng of a plasmid constitutively expressing 514 
Renilla luciferase (pREN-Luc) under the SV40 promoter (26) (kindly provided by 515 
Benjamin G. Hale), as well as 1000ng of the indicated pCAGGS-SAM NS1 516 
expressing plasmids (or empty pCAGGS,1000ng). After 24 h of transfection, cells 517 
were infected with 50 hemagglutinating units (HAU) of SeV for 18 h, then lysed with 518 
250µl of passive lysis buffer (Promega). IFN- β-FF-Luc, ISRE-FF-Luc and REN-Luc 519 
activities were measured using the Dual-luciferase reporter assay system 520 
(Promega), as directed by the manufacturer's protocol. All transfections were carried 521 
out in triplicates, and experiments were repeated independently three times. 522 
Co-immunoprecipitation of NS1 with CPSF30. The equine CPSF30 was cloned as 523 
previously described for the human CPSF30 (18). Briefly, the equine CPSF30 gene 524 
was amplified by RT-PCR from equine cells using oligo d(T) and PCR with specific 525 
primers. The RT-PCR product was then cloned into the pCAGGS HA-COOH plasmid 526 
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 as described previously (36). NS1 proteins were synthesized in vitro using pcDNA3 527 
plasmids and the TNT7 transcription/translation kit (Promega) following the 528 
manufacturer's recommendations. Human 293T cells (1.5 × 106 cells/well, 6-well 529 
format, triplicates) were transiently transfected with 2 µg/well of an HA-equine 530 
CPSF30-expressing pCAGGS plasmid. Fourty-eight hours post-transfection (hpt), 531 
cells were lysed in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.5 mM EDTA, 5% 532 
glycerol, 1% Triton X-100 supplemented with a complete mini protease inhibitor 533 
cocktail (Pierce). Cleared cell lysates were incubated overnight at 4°C with the in 534 
vitro-synthesized O/03 and revertant NS1 proteins and 20 μl of an anti-HA affinity 535 
resin (Sigma). After extensive washing, precipitated proteins were dissociated from 536 
the resin using Laemmli buffer + -mercaptoethanol. Total proteins from cells lysates 537 
were then analyzed by SDS-PAGE and Western blotting as described below, using a 538 
primary specific rabbit polyclonal antibody against NS1 [Genscript] or HA-tag for 539 
CPSF30 (Sigma).  540 
Rescue of recombinant H3N8 EIVs. Viruses were rescued as previously described 541 
(37). Briefly, co-cultures (2:3) of 293T/MDCK cells (6-well plate format, 2 × 106 542 
cells/well) were seeded 24h prior to viral rescue. Cells were transiently co-543 
transfected using TransIT-LT1 (Cambridge Bioscience), with 2.5μg of seven-544 
ambisense O/03 plasmids (pDP2002-PB2, -PB1, -PA, -HA, -NP, -NA, -M) plus 545 
ambisense O/03 NS plasmid (O/03) or the NS revertant constructs (O/03-K186E, 546 
O/03-230 and O/03-K186E-230). At 24 hpt, the medium was replaced by infection 547 
medium. Virus-containing tissue culture supernatants were collected 2 to 3 days pt, 548 
clarified, and used to infect fresh MDCK cells (P1 stock) for 2 to 3 days post-549 
infection. Viral titres of P1 stocks were determined by immunofocus assay (focus 550 
forming units, FFU/ml) in MDCK cells, using the mouse monoclonal anti-NP antibody 551 
 o
n
 D
ecem
ber 19, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
 (clone HB-65, European Veterinary Laboratory), the horseradish peroxidase-552 
conjugated rabbit anti-mouse IgG antibody (AbD Serotec) and TrueBlue peroxidase 553 
substrate (Insight Biotechnology), as previously described (37). These P1 stocks 554 
were then used to grow P2 viral stocks at MOI 0.01 in MDCK for further use in 555 
experiments. For experimental infections, a minimum of two viral stocks for each 556 
virus were rescued and grown independently. The NS segment of each virus was 557 
sequenced by the Sanger method to confirm the sequence of the O/03 or revertant 558 
viruses.  559 
Viral infection. Confluent monolayers of MDCK cells (12-well plate format, 560 
triplicates, 5 × 105 cells/well) or E-derm cells (12-well plate format, triplicates, 2.5 × 561 
105 cells/wells) were infected (MOI 0.01 and 0.1, respectively) with the indicated 562 
viruses and placed at 37°C, 5% CO2. Cells were grown on coverslips for confocal 563 
microscopy. After 1h incubation, cells were washed with PBS and infection medium 564 
was replaced with 500 µl of fresh growth medium. Tissue culture supernatants were 565 
collected at various times pi and stored at -80°C, and cells were fixed in 0.1% 566 
buffered formalin at 4°C for 16h and kept for confocal microscopy or fluorescence-567 
activated cell sorting (FACS) analysis. Each experiment was repeated three times 568 
independently. Viral titres were determined by immunofocus assay in MDCK cells. 569 
Titrations were repeated three times independently, and the mean value and 570 
standard error mean were calculated using GraphPad Prism7.  571 
To measure virus growth kinetics in the presence of an inhibitor of the IFN response, 572 
E-derm cells were treated with Ruxolitinib (Selleck Chemicals). Ruxolitinib was 573 
prepared as 10mM stocks in dimethyl sulfoxide (DMSO), and used at a 574 
concentration of 4µM (27). Treatment was started 24h prior to infection and 575 
maintained at the same concentration for the whole experiment.  576 
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 For plaque phenotype, a confluent monolayer of MDCK cells (6-well plate format, 577 
triplicates, 6.4 × 104 cells/well) were infected with serial dilution (1:2) of the viral 578 
stock of interest and placed at incubation at 37°C, 5% CO2, humidified atmosphere. 579 
Plates were gently rocked every 10 minutes. After 1h incubation, cells were gently 580 
washed with PBS and infection medium was replaced with a 50:50 2.4% Avicell:2X 581 
MEM overlay for a 48h strictly. At 48 hpi, the overlay was discarded, cells were 582 
gently washed 3 times with PBS and fixed with 80% ice-cold acetone solution 583 
(Sigma-Aldrich) for 10 minutes at room temperature. The plates were then let to dry 584 
overnight at room temperature before being treated with 1% Triton (TritonTM X100, 585 
Sigma-Aldrich-Aldrich) X100 PBS solution for 10 minutes at room temperature, 586 
followed by 1 hour of incubation with 10% NGS PBS solution at room temperature. 587 
This was followed by an overnight immunoblotting at 4oC in 10% Normal Goat 588 
Serum plus PBS with a monoclonal anti-influenza A virus nucleoprotein (NP) 589 
antibody (clone HB65, European Veterinary Laboratory, 1/500 dilution) under gentle 590 
agitation. After a 3-step washing with PBS, a horseradish peroxidase-conjugated 591 
rabbit anti-mouse IgG antibody (AbD Serotec, UK, 1/1000 dilution) was used in PBS 592 
solution for a further 4h at room temperature under gentle agitation. A color 593 
development method was used to reveal the immunofocus using the TrueBlue 594 
peroxidase substrate (Insight Biotechnology), where 2ml of substrate was used per 595 
well for exactly 10 minutes, before being stop with tap water. 596 
Viral and cellular protein staining for FACS and confocal microscopy. Cells 597 
were permeabilized with 1% Triton X100 for 10min, and blocked in PBS 10% Normal 598 
Goat Serum (Gibco, Life Technologies) for 1h. Cells were then incubated with anti-599 
influenza A NP protein antibody, rabbit polyclonal anti-NS1 protein antibody 600 
(Genscript) or rabbit STAT1 polyclonal antibody (Santa Cruz) overnight at 4°C. Cells 601 
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 were then washed twice with PBS and incubated for 4h with a rabbit anti-mouse IgG 602 
Alexa fluor 488 (Cell signalling) or donkey anti-rabbit IgG Alexa fluor 555 (Cell 603 
signalling), before FACS analysis (Guava Flow Cytometer, Merck) or fixed in 604 
VECTASHIELD Antifade Mounting Medium with DAPI (Vector laboratories) and 605 
analysed by confocal microscopy.  606 
For confocal microscopy, images were taken with a 63× oil objective on a Zeiss LSM 607 
880 confocal microscope with GaAsP detector. All images were taken with cross-talk 608 
minimized using best signal calculations in Zen software. 3 × 3 tilescans were 609 
collected in three different positions for each sample. The experiment was repeated 610 
three times independently. Images were imported into ImageJ and STAT1 nuclear 611 
localisation was analysed in NP positive cells, with a minimum of 1000 NP-612 
expressing cells were analysed for each sample. The nuclear localisation of STAT1 613 
was analysed using the ‘AND’ function in the image calculator, and was 614 
accomplished by detecting co-localisation signals between STAT1 and DAPI, using 615 
the co-localization threshold function in ImageJ. The quantity of nuclear STAT1 616 
(nSTAT1) was expressed as a percentage of total STAT1 (tSTAT1) in infected cells. 617 
For the representative pictures of nSTAT1, the signal intensity of nSTAT1 was 618 
normalized to O/03-K186E at 8hpi. 619 
SDS-PAGE and Western blotting. Cells were lysed in Laemlli buffer + -620 
mercaptoethanol and stored immediately at -80°C. Samples were boiled for 15 mins 621 
at 95°C prior to polypeptide separation by SDS-PAGE on NuPAGE Novex 4-12% 622 
Bis-Tris protein gels (ThermoFisher Scientific). Proteins were detected by Western 623 
blotting following to transfer to nitrocellulose membranes. The membranes were 624 
blocked for 1h at room temperature in 5% milk TBST 0.1% Tween-20 and 625 
immunoblotted overnight at 4°C in 5% milk TBST-0.1% Tween-20 with the following 626 
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 antibodies: mouse monoclonal anti-Mx1 (clone M143, provided by Dr. Georg Kochs, 627 
University of Freiburg), rabbit polyclonal anti-ISG15 (Proteintech), rabbit polyclonal 628 
anti-NS1 (GenScript), rabbit monoclonal anti-cleaved caspase-3 and rabbit 629 
monoclonal anti-caspase-3 (Cell Signalling), rabbit monoclonal anti-y-Tubulin 630 
(Sigma), mouse monoclonal anti-puromycin (clone 12D10, Millipore), anti-mouse IgG 631 
HRP conjugated (Dako) and anti-rabbit IgG HRP conjugated (Dako). The 632 
chemiluminescent signal was detected using Amersham ECL Prime Western Blotting 633 
Detection Reagent (GE-Healthcare), and captured with ChemiDoc XRS+ System 634 
(Biorad). 635 
Antiviral cytokine production and general protein shutdown. E-derm cells (12-636 
well plate format, triplicates, 2.5 x 105 cells/well) were infected (MOI 0.1) with the 637 
indicated viruses for a total of 72 h. At the indicated times post-infection, 638 
supernatants were collected and stored at -80°C for further analysis by bioassay, 639 
while cells were treated for 1h at 37°C, 5% CO2 with Puromycin (20µg/ml in DMEM, 640 
15% FBS) prior to lysis in Laemlli buffer + -mercaptoethanol and stored at -80°C for 641 
further analysis by western blot. Puromycin is a well-known antibiotic that competes 642 
against aminoacyl tRNA on the ribosome A site (38). As such, puromycin enables 643 
examination of total protein production without requiring transfection, radio-labeling, 644 
or the prior choice of a candidate gene (39). If cells are incubated with puromycin, 645 
lysed and immunoblotted using an anti-puromycin antibody, all the proteins being 646 
produced will be immunostained as puromycin will be incorporated at the C-terminus 647 
of all nascent proteins. For the bioassay, supernatants were UV-inactivated for 5 648 
minutes at room temperature and used to treat fresh E-derm cells (48-well plate 649 
format, 6x104 cells/well, triplicates) for 24h. The cells were then infected with rVSV-650 
GFP virus (2.5 x 102 TCID50) for 8h, then trypsinized and fixed in 0.1% buffered 651 
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 formalin for 16h at 4°C. The percentage of GFP-expressing cells were then analysed 652 
by FACS. For controls, E-derm cells were mock treated or treated with 500 units of 653 
universal type I IFN (uIFN; PBL Assay Science). GFP expression of mock-treated 654 
cells infected with rVSV-GFP was considered as 100% and GFP expression of uIFN-655 
treated cells infected with rVSV-GFP was considered as 0%. Mean values and 656 
standard error means were calculated with GraphPad Prism7. 657 
RNAseq. Confluent monolayers of E-derm cells (12-well plates, triplicates, 2.5 × 105 658 
cells/wells) were infected with O/03 and revertant viruses (MOI 1) or mock infected at 659 
least three times independently. At 8 hpi cells were washed with PBS, 660 
immunostained with the anti-NP antibody and the proportion of infected cells was 661 
determined by FACS. The samples containing a similar proportion of infected cells 662 
were selected for transcriptomic analysis, and cells were lysed with 500µl of TRIzol 663 
(ThermoFisher Scientific) for further RNA extraction. 664 
Total RNA was extracted using the TRIzol method and further purified using the 665 
RNeasy mini spin columns (Qiagen), including an on-column DNase I digestion step 666 
(Qiagen) according to the manufacturer’s protocol. RNA concentration was measure 667 
with Qubit and the Qubit RNA HS Assay Kit (ThermoFisher Scientific) following the 668 
manufacturer's protocol. The ribosomal (r)RNA integrity number was measured 669 
using an Agilent 2100 BioAnalyzer (Agilent Technologies). 670 
4.5ug of total RNA was enriched by selectively depleting rRNA using the 671 
RiboMinusTM Eukaryote Kit v2 (Ambion, Life Technologies). The sequence reads 672 
(GenBank accession number: PRJEB21264) were processed according to the 673 
Tuxedo pipeline (40). Read quality was assessed using FastQC, and TopHat2 and 674 
Bowtie2 were used to map short reads against the Equus caballus 2 genome 675 
(GCA_000002305.1). A list of differentially expressed genes to mock-infected 676 
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 samples was generated using CuffDiff2 (genes with Benjamini Hochberg-p value 677 
<0.05 were considered significant) (41). 678 
Phylogenetic analysis of EIV NS1 sequences. We collected 170 EIV H3N8 NS 679 
sequences from the NCBI Influenza Virus Resource database (sequences available 680 
upon request). We also included four EIV H3N8 NS sequences that we sequenced 681 
for this study (Accession numbers: MF182460, MF182451, MF182443, MF182459) 682 
(42). SeaView Version 4.6.1 (43) was used to align the NS1 coding regions and the 683 
final alignment was edited manually. NEP coding regions were removed from the 684 
alignment. We used BEAST Version 1.8.4 (44) to infer maximum clade credibility 685 
(MCC) trees. We used a strict molecular clock and HKY85+G model of nucleotide 686 
substitution. Each codon position was estimated with separate substitution rates and 687 
nucleotide frequencies. Two individual chains were run until convergence was 688 
achieved. 689 
Statistical analysis. Unless stated otherwise, significance was calculated by Two-690 
way ANOVA followed by Bonferroni's multiple comparisons test. 691 
 692 
[Text word count: 7,301] 693 
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 851 
FIGURE LEGENDS 852 
Figure 1. Functional characterization of evolutionary distinct EIV NS1 proteins. 853 
A schematic representation of three versions of the NS1 protein (early, intermediate 854 
and late) are found throughout EIV evolution. Early NS1 proteins, full length (230 855 
amino acids) harboring E186, were found in EIVs circulating between the 1960s and 856 
1970s; intermediate NS1s, full length with K186, were found in EIVs circulating 857 
between the late 1970s and late 1990s; and late NS1s, truncated at their C-terminus 858 
(219 amino acids) with K186, are found in EIVs isolated since the late 1990s.  (A-D) 859 
Human 293T cells were transiently co-transfected with a pCAGGS expression 860 
plasmid encoding the indicated NS1 proteins (or empty plasmid), together with either 861 
(A) a Firefly luciferase IFN- promoter reporter construct (pIFN--FF-Luc), or (B) a 862 
plasmid expressing the Firefly luciferase under the control of a promoter containing 863 
an IFN-stimulated regulatory element (pISRE-FF-Luc), as well as with a 864 
constitutively active Renilla luciferase (pREN-Luc) expression plasmid. At 24 hpt, 865 
cells were either (A) infected with SeV (+) or mock infected (-), or (B) treated with 866 
universal interferon (uIFN) (+) or mock treated (-) for 18h. (A-B) The relative activity 867 
of the respective FF-Luc activity in cells transfected with (A) the pIFN--FF-Luc or 868 
(B) pISRE-FF-Luc plasmids were determined as the ratio between FF-Luc and REN-869 
Luc in each corresponding sample. Values were normalized to (A) empty pCAGGS 870 
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 plasmid (+) SeV or (B) empty pCAGGS plasmid (+) uIFN (set to 100%). (C) Human 871 
293T cells were transiently co-transfected individually with the indicated NS1-872 
expression plasmids together with pREN-Luc. Total REN-Luc levels were measured 873 
24 h later, and values were normalized to empty pCAGGS transfected cells. (A-C) 874 
Bars represent means and error bars SEM, from three independent experiments. 875 
Significance was calculated as indicated in material and method. ****, p<0.0001 for 876 
pCAGGS+SeV or pCAGGS+uIFN versus all other conditions. £ symbols indicate 877 
significance between indicated NS1 against all other NS1 proteins, with ££, p<0.01; 878 
££, p<0.001; £££, p<0.0001. (D) The level of expression of the indicated NS1 was 879 
analyzed by Western blotting from parallel transfected lysates using a rabbit 880 
polyclonal anti-EIV NS1 antibody. (E) Alignment of NS1 amino acid sequences of 881 
each of the 13 EIVs used in this study. Polymorphism between the 13 NS1 proteins 882 
are indicated in yellow. Red shadings represent NS1 amino acid changes 883 
investigated in the study. Grey shadings show other polymorphisms present at high 884 
frequency in the EIV population.  885 
 886 
Figure 2. NS1 E186 controls general gene expression. 887 
(A) Protein alignment showing the sequence of interest and the introduced mutations 888 
in EIV NS1. Below the alignment there is a diagram of the three different NS1 889 
proteins that represent evolutionary distinct NS1 proteins. An early NS1 (shown in 890 
red) is O/03-230 amino acids long and possesses E186; an intermediate NS1 891 
(shown in light brown) is O/03-230 amino acids long and possesses K186; and a 892 
Late NS1 (shown in blue) is 219 amino acids long and possesses K186. (B) IFN-β, 893 
(C) ISRE, and (D) general gene expression reporter assays were done using the 894 
indicated NS1 pCAGGS expression constructs as described in Figure 1. 895 
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 Experiments were performed three times independently and significance was 896 
calculated as described in material and method. ****, p<0.0001 for pCAGGS+SeV or 897 
pCAGGS+uIFN versus all other conditions. ££££ indicates a significant difference 898 
(p<0.0001) between K186E-containing revertant(s) and O/03 and O/03-230 899 
revertant. €€€€ indicates significance (p<0.0001) between O/03-K186E and all other 900 
conditions, and $$$$ indicates a significant difference (p<0.0001) between O/03 and 901 
O/03-230 revertant. Error bars represent SEM. (E) Western blotting from lysates 902 
from parallel samples was performed as described in Figure 1. 903 
 904 
Figure 3. Amino acid 186 is a determinant of NS1 interaction with CPSF30. 905 
NS1 variants were synthesized in vitro. Human 293T cells were transiently 906 
transfected with 2000ng of a pCAGGS plasmid expressing a HA-tagged version of 907 
the equine CPSF30. At 30 hpt, cells were lysed and cleared cell lysates expressing 908 
HA-CPSF30 were incubated overnight at 4°C with the in vitro-synthesized NS1 909 
proteins and 20 μl of an anti-HA affinity resin. Precipitated proteins were dissociated 910 
from the resin and analyzed by Western blotting. A representative picture of protein 911 
expression levels (‘input’, left panel) and co-immunoprecipitation results (IP anti-HA, 912 
right panel) are shown. 913 
 914 
Figure 4. Characterization of EIVs carrying mutations in NS1. 915 
(A) Schematic representation of the mutations introduced in O/03 NS segment at 916 
NS1 codon 186 and codon 220 (nucleotides 582 to 584 and 684 to 686 in O/03 NS 917 
segment, respectively), and the resulting amino acid changes in the different NS1 918 
proteins (late, artificial, intermediate, early) are indicated. A(n) indicates a poly-A tail, 919 
and ‘*’ indicates a stop codon (TGA). The introduced changes did not change the 920 
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 NEP amino acids at positions 28 (TTA/G coding for leucine) and 68 (AAT/C coding 921 
for asparagine). (B) Growth kinetics of O/03, O/03-K186E, O/03-230, and O/03-922 
K186E-230 viruses in MDCK cells (MOI 0.01) and E-derm cells (MOI 0.1). Data 923 
points represent virus titers in supernatants at different times post-infection and error 924 
bars represent SEM. (C) Plaque phenotype of O/03, O/03-K186E, O/03-230, and 925 
O/03-K186E-230 in MDCK cells at 48 hpi. The average plaque size for each virus 926 
was determined by counting over 100 plaques per condition. Significance was 927 
calculated as described in Methods. +++, p<0.001 for O/03-K186E-230 versus O/03. 928 
****, p<0.0001; ***, p<0.001; **, p<0.01 for O/03 versus three other viruses. £, 929 
p<0.05 for O/03-K186E-230 versus O/03-K186E. (D) Subcellular localization of NS1 930 
in infected equine cells. E-derms were infected with O/03, O/03-K186E, O/03-230, 931 
and O/03-K186E-230 (MOI 0.1) for 24h. NS1 was detected by immunofluorescence 932 
as described in Methods. The experiment was performed three times independently 933 
and representative pictures of NS1 are shown. Scale represents 20m. 934 
 935 
Figure 5. NS1 amino acid 186 and C-terminal tail affect EIV control of general 936 
protein production, apoptosis and response to IFN in equine cells. 937 
E-derm cells were infected (MOI 0.1) with O/03, O/03-K186E, O/03-230, and O/03-938 
K186E-230 viruses. (A) Cells were lysed and immunoblotted for the indicated 939 
proteins at indicated hpi. (B) To measure protein shutoff upon infection, culture 940 
media were replaced with a puromycin-containing suspension and incubated for 1h. 941 
The cells were then lysed and immunoblotted for puromycin at indicated hpi, as 942 
described in Methods. Western blot quantification for puromycin and -tubulin signal 943 
were determined for three independent experiments and expressed relatively to 944 
mock infected cells. Significance was calculated as indicated in material and method. 945 
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 ***, p<0.001 for indicated virus versus all other conditions at 12 hpi. £, p<0.05 for 946 
O/03-K186E-230 versus 230; ££, p<0.01 for O/03-K186E-230 versus O/03-K186E; 947 
£££, p<0.0001 for O/03-K186E-230 versus O/03 and mock. +, p<0.05 for indicated 948 
virus versus mock-infected samples at 24 hpi. Gamma tubulin was used as a loading 949 
control.  950 
 951 
Figure 6. Comparison of growth kinetics and production of antiviral cytokines 952 
in equine cells infected with EIV O/03 and NS1 revertant viruses. 953 
E-derm cells were infected (MOI 0.1) for 72h with (A) O/03, (B) O/03-K186E, (C) 954 
O/03-230, and (D) O/03-K186E-230. Supernatants were collected and cells fixed at 955 
indicated times pi. The total amount of antiviral cytokines produced upon infection 956 
was measured using an IFN bioassay, and virus growth kinetics was determined by 957 
immunofocus assay. Error bars represent SEM. Significance was calculated as 958 
indicated in the Method section. ****, p<0.0001 for indicated virus at indicated time 959 
post infection versus the three other viruses at the same time post infection.  960 
 961 
Figure 7. JAK1/2 inhibition restores growth kinetics of NS1 revertant viruses. 962 
E-derm cells were treated for 24h with uIFN (A) or Ruxolitinib (B) prior to infection 963 
(MOI 0.1) with O/03, O/03-K186E, O/03-230, and O/03-K186E-230. Cells and 964 
supernatants were collected at different times post-infection. Viral titers were 965 
measured as described in Methods. Significance was calculated as indicated in 966 
material and method. ***, p<0.001 and *, p<0.05 for O/03 at indicated time post 967 
infection versus the three other viruses at the same time post infection. 968 
 969 
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 Figure 8. NS1 amino acid 186 and the C-terminal tail affect EIV control of gene 970 
expression in equine cells. 971 
(A) Heat map of differentially expressed genes (DEGs) between O/03 and revertant 972 
virus infected-E-derm cells versus mock-infected samples. |Log2FC|>0.58 and 973 
p<0.05 are regarded as statistically differentially expressed to mock. The total 974 
number of DEGs for each condition is indicated at the bottom of the heat map.  975 
DEGs to mock infected conditions were classified in 11 groups: 1-DEGs shared 976 
between O/03 and mutants; 2-DEGs shared between all viruses but O/03-230; 3-977 
DEGs shared between all viruses but O/03-K186E; 4-DEGs shared between O/03 978 
and O/03-K186E; 5-DEGs shared between O/03 and O/03-230; 6-DEGs shared 979 
between O/03 and O/03-K186E-230; 7-DEGs shared between all revertants; 8-DEGs 980 
present in O/03 only; 9-DEGs present in O/03-K186E only; 10-DEGs present in 981 
O/03-230 only; and 11-DEGs present in O/03-K186E-230 only. The complete list of 982 
genes in presented in Table S1. (B) List of DEGs (including some ISGs) present only 983 
in revertant virus-infected samples (group 7). Values indicate Log2FC. 984 
|Log2FC|>0.58 and p<0.05 are regarded as statistically significant. 985 
 986 
Figure 9.  STAT1 nuclear localization in equine cells infected with EIV O/03 and 987 
NS1 revertant viruses. 988 
E-derm cells were infected (MOI 0.1) with O/03, O/03-K186E, O/03-230, and O/03-989 
K186E-230 viruses or mock infected for 8 or 24h. (A) Top: Confocal images showing 990 
co-immuno-staining of viral NP and STAT1. The experiment was performed three 991 
times independently, and representative pictures of STAT1 and NP are shown. Scale 992 
represents 20m. Bottom: Graphical representation of nuclear localization of STAT1 993 
(nSTAT1). nSTAT1 was quantified as described in materials and methods and 994 
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 expressed as a percentage of total STAT1 (tSTAT1). Statistical significance was 995 
calculated as described in materials and methods. **, p<0.01 for O/03-K186E versus 996 
other conditions at 8 hpi. No other significant differences were detected. (B) Infected 997 
cells were lysed and total STAT1 expression was determined by western blot. 998 
Gamma tubulin was used as a loading control. 999 
 1000 
Figure 10. K186 and C-terminal truncation were fixed at the virus population 1001 
level during EIV NS1 evolutionary history.  1002 
(A) Phylogenetic tree highlighting the fixation of E186K substitution and C-terminal 1003 
truncation. Red branches represent NS1 proteins containing E186 and 230 amino 1004 
acids (Early NS1), and orange branches represent NS1 proteins containing K186 1005 
and 230 amino acids (Intermediate NS1), and blue branches represent NS1 proteins 1006 
containing K186 and 219 amino acids (Late NS1). 1007 
 1008 
 1009 
 1010 
TABLES 1011 
Table 1. Viruses used in this study. 1012 
 
Virus name 
 
Accession number 
 
Abbreviation 
 
A/equine/Uruguay/1/1963 
 
ACD85423 
 
U/63 
A/equine/Miami/1/1963 ABY81497 M/63 
A/equine/SaoPaulo/1/1969 ACD85390 SP/69 
A/equine/Fontainebleau/1/1979 ACD85401 F/79 
A/equine/Sussex/1/1989 ACD97430 S/89 
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 A/equine/Kentucky/1/1991 ACA24672 K/91 
A/equine/LaPlata/1995 MF182460 LP/95 
A/equine/Kentucky/1995 MF182451 K/95 
A/equine/Kentucky/1999 MF182443 K/99 
A/equine/Kentucky/5/2002 ABA42429 K/02 
A/equine/Newmarket/5/2003 ACI48802 N/03 
A/equine/Ohio/1/2003 ABA42431 O/03 
A/equine/Mongolia/3/2013 MF182459 M/13 
 1013 
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